<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741702</url>
  </required_header>
  <id_info>
    <org_study_id>231-2001</org_study_id>
    <nct_id>NCT00741702</nct_id>
  </id_info>
  <brief_title>Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples</brief_title>
  <acronym>DREAM3</acronym>
  <official_title>Diabetes Risk Evaluation and Microalbuminuria in Saskatchewan First Nations Peoples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial was designed to assess whether a community-based treatment
      strategy implemented by home care nurses would be effective in controlling hypertension in
      First Nations people with existing hypertension and type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two community-based strategies for controlling hypertension in First Nations people with
      existing hypertension and diabetes were compared. In the intervention group, a home care
      nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy. In
      the control group, treatment decisions were made by each subject's primary care physician.
      The primary outcome measure was the difference between the 2 groups in teh change in systolic
      blood pressure after 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure, change in urine albumin status and incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nurse administered treatment algorithm</intervention_name>
    <description>Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP &gt;=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP&gt;= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP&gt;=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP&gt;=13/80 mm Hg, increase verapamil to 240 mg/d</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;= 18 yr

          -  Type 2 diabetes mellitus

          -  Persistent hypertension (systolic pressure &gt;= 130 mmHg, diastolic pressure &gt;= 80 mm
             Hg, or both)

        Exclusion Criteria:

          -  use of beta blocker

          -  women of child-bearing age not able to use a reliable method of birth control

          -  Connective tissue disorder

          -  Severe systemic or malignant disease

          -  Inability to follow the protocol

          -  Bilateral renal artery stenosis and other causes of secondary hypertension

          -  Serum creatinine level &gt; 250 micromol/L

          -  cerebrovascular even within 6 mo

          -  valvular heart disease

          -  unstable angina

          -  Myocardial infarction

          -  Revascularization procedure within 3 mo before study recruitment

          -  heart failure

          -  cardiac arrhythmia requiring medical treatment or heart block

          -  active hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon Tobe, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Sheldon Tobe</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>First Nations populations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

